UBS Maintains a 'Buy' on Life Technologies (LIFE); Navigenics Acquisition Announcement
Tweet
Share
E-mailGet Alerts LIFE Hot Sheet
Price: $1.60 -1.23%
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
6 Buy, 4 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
UBS maintains a 'Buy' on Life Technologies (NASDAQ: LIFE) price target of $53.00.
Analyst, Daniel Arias keeps his rating on shares of LIFE, noting yesterday's acquisition announcement of Navigenics.
"The advent of personalized medicine will require a combination of technologies and informatics focused on delivering relevant information to the treating physician," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "Navigenics has pioneered the synthesis and communication of complex genomic information, and we will now pivot the company's effort to date and focus on becoming a comprehensive provider of technology and informatics to pathologists and oncologists worldwide."
Navigenics' extensive clinical program provides Life Technologies with a leadership position in clinician and patient education and support, which will be leveraged by Life Technologies in building its diagnostics business. The platform includes a network of oncologists, pathologists, and genetic counselors, who will be available to support community-based physicians in the adoption of genetic medicine and assist them in understanding these innovative types of medical information.
Navigenics, Inc. develops and commercializes genetics-based products and services to improve individual health.
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $43.15 yesterday.
Analyst, Daniel Arias keeps his rating on shares of LIFE, noting yesterday's acquisition announcement of Navigenics.
"The advent of personalized medicine will require a combination of technologies and informatics focused on delivering relevant information to the treating physician," said Ronnie Andrews, president of Medical Sciences at Life Technologies. "Navigenics has pioneered the synthesis and communication of complex genomic information, and we will now pivot the company's effort to date and focus on becoming a comprehensive provider of technology and informatics to pathologists and oncologists worldwide."
Navigenics' extensive clinical program provides Life Technologies with a leadership position in clinician and patient education and support, which will be leveraged by Life Technologies in building its diagnostics business. The platform includes a network of oncologists, pathologists, and genetic counselors, who will be available to support community-based physicians in the adoption of genetic medicine and assist them in understanding these innovative types of medical information.
Navigenics, Inc. develops and commercializes genetics-based products and services to improve individual health.
For an analyst ratings summary and ratings history on Life Technologies click here. For more ratings news on Life Technologies click here.
Shares of Life Technologies closed at $43.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
- Comerica (CMA) PT Raised to $54 at Piper Sandler
- Westamerica Bancorp (WABC) PT Lowered to $50 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
